University of Queensland Archives - CanPath - Canadian Partnership for Tomorrow’s Health

CanPath – Canadian Partnership for Tomorrow’s Health Search

About Us
- Purpose, Vision & Mission
  CanPath is working in partnership to prevent disease and provide a platform for scientists to conduct innovative research.
- Our History
  The Canadian Partnership Against Cancer established the Canadian Partnership for Tomorrow Project (now CanPath) in June 2008.
- Leadership & Governance
  Meet the members of CanPath's Leadership Team, Operations Committee, National Strategic Advisory Council and more.
- National Coordinating Centre
  Meet the members of CanPath's operational core, based at the University of Toronto's Dalla Lana School of Public Health.
- Student Work and Opportunities
  Students are a cornerstone of our population health research program, driving innovation and discovery as the next generation of researchers and health professionals.
- Regional Cohorts
  Seven regional cohorts across ten provinces comprise CanPath's pan-Canadian partnership.
- Funders & Supporters
  Learn more about the partner organizations that provide funding and in-kind support to CanPath.
- Frequently Asked Questions
  Find out how CanPath will improve the health of Canadians and more.
- Contact Us
  How to reach CanPath by phone, email, in-person, or make a data access request.
Research
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- Access Process
  The CanPath Access Portal provides researchers with the necessary resources to identify epidemiological and biological data available from participating cohorts to answer innovative research questions.
- Approved Projects & Studies
  CanPath has supported more than 100 research projects and activities, many of which have resulted in publications in high impact journals.
- Collaborations
  The CanPath team is committed to collaborating with partners in order to enhance and accelerate research for a healthier Canada.
- COVID-19 Initiatives
  As Canada’s largest population health study, CanPath responded quickly to the pandemic by leveraging its existing infrastructure to support national COVID-19 research.
- Funding & Grant Opportunities
  Supporting researchers and innovators who are seeking financial backing and collaborative opportunities for their projects utilizing CanPath data
- Policies
  CanPath requires approved users of its data to conduct research that follows and conforms to all data use policies. Approved users should read, understand, and follow the policies below.
- Publications
  These publications are examples of research made possible with data from CanPath and its regional cohorts.
- Synthetic Dataset
  The CanPath Synthetic Dataset is a versatile resource designed for research, education, and practical applications, offering robust support and guidance for educators to integrate it into their curriculum.
Participants
- About the Study
  CanPath is Canada’s largest population health cohort and a gateway platform to data worldwide.
- COVID-19 Antibody Study FAQ
  CanPath and its regional cohorts are conducting a COVID-19 antibody study of 20,000 participants across Canada.
- HEALthy Eating and Supportive Environments (HEAL) Study
  CanPath and its regional cohorts are conducting one of the biggest dietary intake and physical activity data collection efforts in Canada: the HEALthy Eating and Supportive Environments (HEAL) study.
- Meet CanPath Participants
  Hundreds of thousands of Canadians have come together to be part of a study that reveals real breakthroughs.
- Participant Snapshot
  Understand the unique social, economic and health characteristics of CanPath participants and how this information is captured for research.
News & Events
CanPath Access Portal

Newest to Oldest
Oldest to Newest

2025

Evaluating practical approaches for including MYOC variants alongside common variants for genetics-based risk stratification for glaucoma: Including MYOC Variants for Glaucoma Risk Stratification

Authors: N. Q. Le, W. He, M. H. Law, S. E. Medland, D. A. Mackey, A. W. Hewitt, P. Gharahkhani, S. MacGregor

The researchers investigated methods for identifying carriers of the p.Gln368Ter variant in the MYOC gene, associated with glaucoma risk, using data from the Genetics of Glaucoma (GOG), the QSkin Sun and Health Study (QSKIN), and CARTaGENE cohorts. They found that direct genotyping, with proper quality control measures, showed high accuracy and perfect concordance with sequencing data. Incorporating p.Gln368Ter status into polygenic risk scores (PRS) significantly improved risk stratification for carriers, increasing the proportion classified as high-risk in QSKIN and CARTaGENE. However, adding this variant to PRS did not enhance overall risk prediction for the general population.

Read Publication